Print

Print


Mutations in the Glucocerebrosidase Gene and Parkinson's Disease in
Ashkenazi Jews
Judith Aharon-Peretz, M.D., Hanna Rosenbaum, M.D., and Ruth Gershoni-
Baruch, M.D.

The New England Journal of Medicine
Volume 351:1972-1977            November 4, 2004                Number 19

ABSTRACT

Background A clinical association has been reported between type 1
Gaucher's disease, which is caused by a glucocerebrosidase deficiency
owing to mutations in the glucocerebrosidase gene (GBA), and
parkinsonism. We examined whether mutations in the GBA gene are
relevant to idiopathic Parkinson's disease.

Methods A clinic-based case series of 99 Ashkenazi patients with
idiopathic Parkinson's disease, 74 Ashkenazi patients with
Alzheimer's disease, and 1543 healthy Ashkenazi Jews who underwent
testing to identify heterozygosity for certain recessive diseases
were screened for the six GBA mutations (N370S, L444P, 84GG, IVS+1,
V394L, and R496H) that are most common among Ashkenazi Jews.

Results Thirty-one patients with Parkinson's disease (31.3 percent;
95 percent confidence interval, 22.2 to 40.4 percent) had one or two
mutant GBA alleles: 23 were heterozygous for N370S, 4 were
heterozygous for 84GG, 3 were homozygous for N370S, and 1 was
heterozygous for R496H. Among the 74 patients with Alzheimer's
disease, 3 were identified as carriers of Gaucher's disease (4.1
percent; 95 percent confidence interval, 0.0 to 8.5 percent): 2 were
heterozygous for N370S, and 1 was heterozygous for 84GG. Ninety-five
carriers of Gaucher's disease were identified among the 1543 control
subjects (6.2 percent; 95 percent confidence interval, 5.0 to 7.4
percent): 92 were heterozygous for N370S, and 3 were heterozygous for
84GG. Patients with Parkinson's disease had significantly greater
odds of being carriers of Gaucher's disease than did patients with
Alzheimer's disease (odds ratio, 10.8; 95 percent confidence
interval, 3.0 to 46.6; P<0.001) or control subjects (odds ratio, 7.0;
95 percent confidence interval, 4.2 to 11.4; P<0.001). Among the
patients with Parkinson's disease, patients who were carriers of
Gaucher's disease were younger than those who were not carriers (mean
[±SD] age at onset, 60.0±14.2 years vs. 64.2±11.7 years; P=0.04).

Conclusions Our results suggest that heterozygosity for a GBA
mutation may predispose Ashkenazi Jews to Parkinson's disease.

Source Information

From the Department of Neurology and the Cognitive Neurology Unit
(J.A.-P.) and the Departments of Hematology and Bone Marrow
Transplantation (H.R.) and Human Genetics (R.G.-B.), Rambam Medical
Center; and the Bruce Rappaport Faculty of Medicine, Technion–Israel
Institute of Technology (J.A.-P., H.R., R.G.-B.) — both in Haifa,
Israel.

Address reprint requests to Dr. Gershoni-Baruch at the Department of
Medical Genetics, Rambam Medical Center, Haifa 31096, Israel, or at
[log in to unmask]

Full Text of this Article
http://content.nejm.org/cgi/content/full/351/19/1972

SOURCE: The New England Journal of Medicine
http://tinyurl.com/53rcb

* * *Murray Charters <[log in to unmask]>
Please place this address in your address book
Please purge all others

Web site: Parkinsons Resources on the WWWeb
http://www.geocities.com/murraycharters

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn